The main purpose of this legislative text is to update and reauthorize a program aimed at preventing and treating sickle cell disease, which is a serious genetic blood disorder. The goal is to improve health outcomes for individuals affected by this condition and to address its complications. Key provisions of the legislation include changes to how the program operates. It expands the focus from just the treatment of sickle cell disease to also include the prevention and treatment of complications that arise from the disease.